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EPIGRAPH  
 
 
“Eles não sabem, nem sonham, 
Que o sonho comanda a vida, 
Que sempre que um homem sonha 
O mundo pula e avança 
Como bola colorida 
Entre as mãos de uma criança” 
 
António Gedeão 
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RESUMO  
Introdução: A obesidade é, atualmente, uma pandemia à escala mundial, afetando 
crianças e adolescentes, produzindo múltiplas comorbilidades, uma das quais o Fígado 
Gordo Não-Alcoólico (NAFLD), cuja prevalência tem aumentado enormemente nos 
últimos anos. Na verdade, este aumento tem até ocorrido de forma mais acentuada do 
que o da obesidade e o consumo de frutose aparenta ser o fator de risco mais 
importante. Existem várias causas secundárias de esteatose hepática, mas devido à 
grande prevalência de fígado gordo associado à obesidade ou tipo de dieta, o diagnóstico 
de outras entidades clínicas torna-se difícil. Este diagnóstico torna-se especialmente 
importante quando se tratam de patologias com tratamento específico, como é o caso da 
Glicogenose tipo IX (GSD-IX).  
Objetivos: Contribuir para o conhecimento dos diagnósticos diferenciais de NAFLD em 
idade pediátrica. Contribuir para a caracterização clínica, bioquímica, molecular e 
histológica, da GSD-IX, uma doença metabólica rara.  
Metodologia: Estudo retrospectivo, a partir dos registos clínicos, de uma pequena série 
de casos (n=3) de GSD-IX, diagnosticados nos últimos 6 anos, atualmente em 
seguimento nas Unidades de Gastrenterologia ou de Doenças Metabólicas do Serviço de 
Pediatria do nosso hospital, e cuja forma de apresentação clínica foi NAFLD em idade 
pediátrica.  
Resultados: Três doentes de sexo masculino, com apresentação de NAFLD antes dos 2 
anos de idade, dois com diagnóstico confirmado antes dos 3 anos e um cujo diagnóstico 
só foi confirmado aos 11 anos. Nenhum dos doentes era obeso ou tinha excesso de 
peso; o consumo diário de frutose é desconhecido. A evolução foi favorável nos três 
doentes, com um tempo de seguimento que variou entre 2 e 6 anos.  
Conclusões: Decidir até onde deve prosseguir a investigação de causas secundárias de 
NAFLD pode ser muito difícil. A GSD-IX deve fazer parte da lista de causas possíveis. 
 
Palavras-chave: Glicogenose tipo IX; Fígado Gordo não Alcoólico; Esteatohepatite; 
Crianças 
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ABSTRACT  
Background: Obesity is currently a worldwide pandemic, affecting children and 
adolescents, producing multiple co-morbidities, one of which is Non-Alcoholic Fatty Liver 
Disease (NAFLD), whose prevalence has increased dramatically in recent years. In fact, 
this increase has even occurred more markedly than with obesity, and fructose 
consumption appears to be the most important risk factor. There are several secondary 
causes of hepatic steatosis, but due to the high prevalence of fatty liver associated with 
obesity or type of diet, diagnosis of other clinical entities becomes difficult. This diagnosis 
becomes especially important when dealing with pathologies with specific treatment, such 
as glycogenosis type IX (GSD-IX). 
Aims: Contribute to the knowledge of differential diagnosis of NAFLD in Pediatric age. 
Contribute to the clinical, biochemical, molecular and histological characterization of GSD-
IX, a rare metabolic disorder. 
Methods: A retrospective study of a small series of cases (n = 3) of GSD-IX diagnosed in 
the past 6 years, currently being followed up in the Units of Gastroenterology or Metabolic 
Diseases of the Pediatric Division of our hospital, and whose clinical presentation was 
NAFLD in Pediatric age. 
Results: Three male patients with NAFLD before 2 years of age, two with confirmed 
diagnosis before age 3 and one whose diagnosis was confirmed at 11 years-old. None of 
the patients were obese or overweight; the daily consumption of fructose intake is 
unknown. The outcome was favourable in all of three patients, with follow-up period 
ranging from 2 to 6 years. 
Conclusion: Deciding how far to investigate NAFLD secondary causes can be quite 
difficult, and GSD-IX should be on the list of possible causes. 
 
Keywords: Glycogenosis type IX; Non-alcoholic fatty liver disease; steatohepatitis; 
children 
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INTRODUCTION 
 
The worldwide increase in the prevalence of childhood and juvenile obesity leads 
many patients to present with comorbidities in the Pediatric age (1, 2). Among these, non-
alcoholic fatty liver disease (NAFLD) is increasing at an even faster rate than obesity 
(incidence 34,2% in obese children; 7,6% in general population), and is already the most 
common cause of chronic liver disease in children and adolescents (3). Unfavourable 
lifestyles, particularly a high-fructose diet, may be the cause (4); Mediterranean diet 
appears to reduce the risk for non-alchoolic steatohepatitis (NASH) in obese Pediatric 
patients(5). NAFLD may progress to fibrosis, culminating in the long term in cirrhosis and is 
projected as the primary indication for liver transplantation in the future (6).   
NAFLD is characterized by fatty infiltration of the liver in the absence of alcohol or 
drug consumption, infections, malnutrition, and genetic/metabolic diseases. Therefore, 
diagnosis should only be assumed after excluding other causes, especially those with 
specific treatment (7). Among the metabolic diseases to be considered are some 
glycogenosis (8).  
Glycogenosis type IX (GSD-IX), one of the most common forms of glycogenosis 
(25% of cases; estimated frequency of 1/100 000), is caused by deficiency in hepatic 
phosphorylase kinase (PhK), which is composed by four subunits (, , , ); GSD-IX 
subtypes are identified according to the affected subunit. Transmission can be linked to 
chromosome X (PHKA2 gene, 75% of all GSD-IX, subtype ,) or be autosomal recessive 
(gene PHKB, subtype ; gene PHKG2, subtype ). Although the main substrate 
accumulated in the target organs is glycogen, there may be a predominance of lipids, 
particularly in the liver (9, 10).  
We describe a small series of cases (n=3) of GSD-IX, subtype α, diagnosed and 
followed in the past 6 years, in the Pediatrics Division of our hospital, whose clinical 
presentation was NAFLD in Pediatric age. 
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CASE REPORTS  
 
Case1  
 
A male infant, first child of a healthy couple, was born after a 40-week pregnancy, with 
weight 3080g (p10-50) and length 48,5 cm (p10). At 18 months-old, he was hospitalized 
for pneumonia, presenting with hepatosplenomegaly and elevated transaminases 
[Aspartate Aminotransferase (AST) 67 UI/L, Alanine Aminotransferase (ALT) 53 UI/L]. 
Later-on, AST and ALT normalized but persistent hepatosplenomegaly lead to admission 
at our outpatient clinic by 25 months-old. At this moment, complementary investigation 
including lipidogramme, alpha-1-antitrypsin, creatine phosphokinase (CPK), 
ceruloplasmin, Hepatitis C virus antibodies was normal. Throughout the following years, 
spleen dimensions returned to normal, but the liver remained slightly enlarged with hyper-
echogenicity. At 5 years-old, enzymatic activity in leucocytes for glycogenosis type III 
(GSD-III) was normal. He was discharged to his attending physician, and recommended 
to perform yearly abdominal ultrasounds. By 11 years-old, abdominal ultrasound revealed 
diffuse liver hyperechogenicity, suggesting steatosis. Laboratory tests performed are 
displayed in table 1. Liver histology revealed macro and micro-steatosis without 
inflammatory infiltrates or fibrosis (Fig.1). Copper in liver tissue was normal. Molecular 
study confirmed the previously described mutation c.1054C>T (p. 352X) exon 11 in 
hemizygosity on the PHKA2 gene. Dietary measures were prescribed. Currently, he’s 17 
years-old: transaminases remain normal; liver maintains steatosis pattern, with no 
adenomas; spleen is in the upper limit of normal size.  
 
Case 2 
 
A male infant, second child of a healthy couple, was born after a 37-week pregnancy with 
weight 2750g (p10-50) and length 46,5 cm (p10-50). He developed physiological jaundice 
that resolved within a week without phototherapy. During his first months, he had several 
episodes of wheezing, treated with Montelukast and fluticasone in aerosol.  At 11 months 
of age, during a wheezing episode, transaminases (AST 158 Ul/L; ALT 155 Ul/L) and 
triglycerides (180 mg/dl) were elevated. At 15 months, he was admitted to our hospital for 
hepatomegaly (6cm below the costal grid, smooth surface, thin edge) and persistently 
elevated transaminases; abdominal ultrasound showed an enlarged and hyperechogenic 
liver with steatosis pattern; spleen was normal-sized. From laboratory tests we highlight 
the slightly low fasting glycemia and bicarbonate, discretely raised triglycerides and 
normal serum uric acid (table 1). Cardiac evaluation was normal. Molecular study showed 
a previously described causal mutation on the PHKA2 gene [c.892C>T (p. R298X - exon 
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9)] with hemizygosity pattern, confirming GSD-IXa. Dietary measures were prescribed. 
Two years later, hepatomegaly remained equal, although transaminases normalized; 
bicarbonates were slightly low and uric acid elevated. Patient emigrated to France and 
was lost from follow-up since. 
 
Case 3  
 
A male infant, first child of a healthy couple, was born after a 39-week high-risk pregnancy 
due to placental displacement, with weight 3300g (p10-50) and length 51cm (p50). In the 
first week, he developed jaundice (total bilirubin 17,3 mg/dl) treated with phototherapy. 
During the first 8 months he had multiple infections: Escherchia coli urinary tract 
infections, acute gastroenteritis, fever of undetermined origin, Neisseria meningitidis 
sepsis, Coronovirus upper respiratory infection, Proteus cystitis, acute bronchiolitis 
followed by acute otitis media and an episode of bacteriemia of unknown origin. This 
overwhelming amount of infections led to an investigation for complement deficiency, 
which showed reduced levels of total haemolytic complement assay (CH50) and alternate 
Pathway Haemolytic assay (AH50) and slightly increased C3 (174mg/dl) and C4 
(48mg/dl), but no other immunological abnormalities. Throughout all these infectious 
episodes, patient had palpable hepatomegaly and consistently elevated transaminases. At 
18 months, abdominal ultrasound showed an enlarged liver with steatosis pattern and a 
normal-sized spleen. Laboratory tests performed are displayed in table 1. A year later, 
molecular study confirmed the new and unrecognized mutation c.706G>T (p. E236*) exon 
7 in hemizygosity in the PhKA2 gene, which leads to the production of a truncated protein. 
His mother is a carrier in heterozygosity. Diet measures were prescribed. Currently, he’s 5 
years-old and doing very well, with slight hepatomegaly (2 cm below costal margin), 
normal ALT (Fig.2) and steatosis pattern on ultrasound. 
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DISCUSSION  
 
NAFLD is one of the comorbidities of obesity and its incidence is increasing 
dramatically. In addition, NAFLD has been associated with a certain dietary pattern, even 
without obesity or overweightness. Nonetheless, it can also be secondary to a large 
number of other entities (7). Thus, a child with NAFLD, whether obese/overweight or not, 
becomes a challenge in terms of differential diagnosis. 
The first struggle is to be certain of the presence of liver steatosis or 
steatohepatitis by non-invasive methods. ALT is currently the best screening method for 
fatty liver in children >10 years-old, with 88% sensitivity and 26% specificity for values >2 
times the normal value(11). Liver ultrasound may show a suggestive pattern but has low 
sensitivity. Liver histology, despite being the gold standard, is too invasive for a screening 
method (12).   
None of our three patients were obese or overweight. All were symptomatic very 
early in life, with hepatomegaly and elevated transaminases, and liver ultrasound showing 
a pattern suggestive of steatosis. Only patient 1 had fatty liver confirmed through liver 
histology at 11 years-old, when raised level of 24h urinary copper obliged to disclose 
Wilson’s disease (13).  
The second struggle is the differential diagnosis approach for fatty liver. The 2017 
North American Society of Pediatric Gastroenterology, Hepatology and Nutrition 
(NASPGHAN) guidelines for diagnosis and treatment of NAFLD (12) don’t provide enough 
orientation for a cost-benefit approach, regarding who and when should be screened for 
each listed genetic/metabolic disease. Furthermore, GSD-IX isn’t even mentioned as a 
secondary cause of fatty liver.  
In this case-series we took into account the age of the patients and prioritized the 
exclusion of diseases with specific treatment. Patient 1, at 11 years-old had been GSD-III 
excluded. Besides GSD types VI and IX and lysosomal acid lipase deficiency (LAL-D) (14), 
we also searched for Wilson’s disease and juvenile haemochromatosis. In patient 2, the 
hypothesis of drug hepatotoxicity for Montelukast was considered, which could explain 
raised transaminases, but probably not hepatomegaly and steatosis. In patient 3, we 
considered the hypothesis of congenital immunodeficiency with liver injury, which wasn’t 
confirmed. For the last 2 patients, LAL-D was also a possible cause, but was only tested 
on patient 3, since patient 2 was lost from follow-up. 
Diagnosis of GSD-IXa was confirmed by molecular study in all patients. All had X-
linked transmitted pathogenic mutations in the PHKA2 gene. In case 2 a new mutation 
was found, that leads to a premature stop codon, being accepted as a causal mutation. 
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GSD-IX clinical presentation is generally milder compared to other GSDs, (and 
very similar to GSD-VI), and symptoms (hepatomegaly, growth retardation, elevated 
transaminases, hypertriglyceridemia and sometimes ketosis and hypotonia) typically 
improve with age, being asymptomatic in adulthood(15). However, genetic variants in 
PHKA2 have a broad phenotypic spectrum, including progression to cirrhosis (16, 17) and 
development of hepatic adenomas(18), as well as less common phenotypes with kidney 
dysfunctions due to renal tubular acidosis and central nervous system involvement with 
delayed cognitive and speech abilities (19). So far, our patients’ clinical course has been 
very benign. 
Treatment consists in dietary measures, such as avoiding prolonged fastings and, 
when needed, drinking infusion with maltodextrin. More rarely, hyperuricemia or metabolic 
acidosis must be addressed. Untreated children may have undesirable repercussions 
such as morning sickness, which affects school performance, and growth retardation, 
causing psychological distress (20). 
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CONCLUSION 
 
In summary, deciding when and how to search for secondary causes of NAFLD 
can be extremely difficult. All contributions to establish guidelines, possibly even an 
algorithm, are extremely important, making this task easier and more cost-effective. Also, 
GSD-IX should be included in these guidelines as a possible cause, as it can cause a 
spectrum of lesions from steatosis and steatohepatitis to cirrhosis. 
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APPENDIX  
Table I - Baseline clinical and analytical features of patients at admission in reference centre 
Clinical features Case 1 Case 2 Case 3 
Reference 
values 
Sex M M M  
Age (year of birth) 11 years 15 months 18 months  
Parental consanguinity No No No  
Family history negative negative negative  
Weight (kg) / percentil 43,6 / p50-85 11,0 / p50-85 11,0 / p50  
Length or Height (cm) / percentil 150,5 / p85 80 / p50-85 82 / p50  
BMI (kg/m
2
) / percentile 19,25 / p50-85 17,2 / p50-85 16,4 / p50-85  
Hepatomegaly No Yes (5 cm) Yes (3,5 cm)  
Splenomegaly No No No  
Biochemical parameters 
Total bilirubin (mg/dl) 0,28 0,16 0,26 0,20 – 1,00 
Conjugated bilirubin (mg/dl) 0,10 0,06 0,10 0,00 – 0,20 
AST (UI/L) 26 150 158 10 – 34 
ALT (UI/L) 16 219 60 10 – 44 
GT (UI/L) 13 35 24 10 – 66 
CPK (UI/L) 136 95 NA 24 -  204 
Glucose (mg/dl) 77 66 74 70-105 
Bicarbonates (mmol/l) 17,5 17,9 15,4 22,0 – 29,0 
Lactate NA 1,28 1,63 0,5 – 2,20 
Uric acid 4,7 3,4 4,0 2,0 – 5,5 
Total cholesterol (mg/dl) 174 174 196 0 – 200 
LDL-cholesterol (mg/dl) 94 116 136 0 – 130 
HDL-cholesterol (mg/dl) 70 13 25 35 – 55 
VLDL-cholesterol (mg/dl) 10 45 35 3 – 56 
Triglycerides (mg/dl) 50 50 227 174 40 – 160 
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Other exams performed after 
Hepatitis A, B, and C 
CMV 
EBV 
Negatives 
IgG+  IgM- 
IgG+  IgM- 
Negatives 
IgG-  IgM- 
IgG-  IgM- 
Negatives 
IgG+  IgM- 
IgG+  IgM- 
 
Serum alfa-1-antitrypsin (mg/dl) Normal Normal normal  
Serum ferritin (ng/mL) 22 NA NA 12,8-454 
Transferrin saturation rate (%) 10 NA NA 15-45 
Serum ceruloplasmin (mg/dl) 26 NA NA 16-36 
Urinary copper 24h (mol/d) 1,086 ND ND 
0,040-
0,050 
Copper in liver tissue (µg/g) 24,82 ND ND <40 
Sweat-test ND Normal ND  
LAL activity (in leucocytes) Normal ND Normal  
Molecular studies 
PHKA2 gene 
Mutation 
c.1054C>T (p. 
352X) exon 11 in 
hemizygosity 
Mutation 
c.892C>T (p. 
R298X) exon 9 in 
hemizygosity 
Mutation 
c.706G>T (p. 
E236*) exon 7    
in hemizygosity 
 
 
Legend: BMI – body mass index; CMV - Citomegalovirus; EBV -  Epstein-barr virus; HDL – high-
density lipoprotein; LAL –lysosomal acid lipase; LDL – low-density lipoprotein; NA – Non-Available; 
ND – Not-Done; VLDL – very low-density lipoprotein; GT – gamma-glutamyl transferase 
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Fig.1 – Liver histology by 11 years-old in case 1, showing macro and micro-steatosis; hepatocytes 
with preserved morphology and dimensions within normal ranges, without inflammatory infiltrate or 
fibrosis. 
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Fig.2 – Transaminases during follow-up in case 3 
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